Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/55661
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3392]
Metadata
Show full item record
TRADITIONAL USE OF BENZNIDAZOLE WITH WEEKLY CLINICAL FOLLOW-UP INDICATE TO BE AN IMPORTANT APPROACH FOR THE ETIOLOGIC TREATMENT OF CHAGAS DISEASE
Silva, Gilberto Marcelo Sperandio da | Date Issued:
2022
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Abstract
Despite more than 100 years of the description of Chagas disease (CD), it still affects about 6 to 7 million people
worldwide, most of them, about 6 million in Latin America. The CD estimated prevalence in
Brazil for 2020 is about 1.3 to 3.2 million individuals. CD can be associated with situations of poverty, when the kissing bug invades the house and feeds on the human
host, infecting it with the flagellate protozoan Trypanosoma cruzi, the agent of CD. In general, benznidazole (BZN) is the most used drug for etiologic treatment in Brazil, indicated for all age
groups when the patient is in the acute phase and, in the chronic phase, for individuals under 50 years of age without
advanced heart disease. Nifurtimox (NFx) would be an alternative for patients who are intolerant to BZN.
Share